Latest Conference Coverage
Patients discharged with home health or to a skilled nursing facility also were more likely to be readmitted.
At the end of a 22-year study period, the 1- and 3-year risk of graft loss did not differs significantly between black and white recipients.
Study reveals a 13% incidence of CIN in allograft recipients undergoing computed tomography or cardiac catheterization with contrast media.
A 30% decline in eGFR between 1 and 3 years post-transplant is associated with an increased risk of all-cause graft loss and patient death.
Study of renal transplant patients also shows that proton pump inhibitors are associated with increased arterial stiffness.
Recipients of diabetic donor kidneys—especially diabetic recipients—are at increased risk of graft loss and death.
Recipients of AKI kidneys have patient and graft survival rates similar to those of recipients of non-AKI kidneys.
Kidney recipients who lost the most weight prior to transplantation had a 25% decreased risk versus those with the most weight gain.
Recipients aged 65 years and older who receive kidneys from donors in the same age group have a higher risk of death and delayed graft function.
Use of these agents is associated with a much lower incidence of hypercalcemia compared with the use of calcium carbonate or calcium acetate.
Meta-analysis reveals a significantly increased risk of kidney stones only in male patients with kidney cancer.
Calciphylaxis was 75% less likely to develop in patients who received the drug rather than placebo.
Over 52 weeks, the drug maintained hemoglobin levels while decreasing IV iron use in dialysis patients with anemia.
Researchers in the Netherlands report results from an autopsy study of diabetic nephropathy patients.
In adjusted analyses, serum phosphorus levels independently predicted glucose disposal rate.
Flexible ureteroscopy achieved a stone-free rate nearly twice as high as that achieved with extracorporeal shock wave lithotripsy.
Adjuvant chemotherapy is associated with better survival among patients with advanced nonmetastatic bladder cancer.
Low-dose-rate brachytherapy boost (LDR-PB) achieves better rates of biochemically disease-free outcomes in prostate cancer.
Adding short-term androgen deprivation therapy to radiotherapy does not improve overall survival in intermediate-risk prostate cancer.
Adding bicalutamide improves overall survival among patients with advanced nonmetastatic hormone-naïve prostate cancer.
Cancer-specific and overall survival is decreased in men with intermediate-risk versus low-risk tumors.
Overweight or obese patients treated with targeted therapy for metastatic clear-cell renal cell carcinoma found to live longer.
In a study of 4,736 patients with metastatic renal cell carcinoma, use of the drugs was associated with a nearly 22% decreased risk of death.
Sorafenib or sunitinib given after surgery for advanced renal cell carcinoma does not improve progression-free survival, study shows.
Researchers observed a significant 36% decreased overall and prostate cancer-specific mortality.
It has implications for treatment decisions and prognosis.
In a phase 2 trial, 72% of patients with high-grade clinical nonmuscle-invasive bladder cancer had a complete response at 3 months.
The 4Kscore enables better identification of men who harbor high-grade prostate cancer.
The 5-year risk of overall mortality is decreased by 50% compared with androgen deprivation therapy alone.
This medication sequence was associated with longer progression-free and overall survival compared with the reverse.
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)